| 摘要 |
A patient with a disorder involving endothelial dysfunction associated with deficient nitric oxide bioactivity, e.g., coronary artery disease, atherosclerosis, hypertension, diabetes or neurodegenerative condition stemming from ischemia and/or inflammation, is treated by administering nitr ic oxide bioactivity increasing agent having formula (I) wherein R1, R2, R3 and R4 are the same or different and are independently selected from the group consisting hydrogen, amino, imino, alkyl, substituted alkyl, phenyl, substituted phenyl, cycloalkyl, benzyl, acyl, pyridyl, piperidyl, amino acid , lipid and carbohydrate and where R3 and R4 can optionally join to form a rin g. Treating agents include N.omega.-hydroxyarginine and hydroxyguanidine.</SDOA B>
|
